SOUTH EASTON, Mass., March 14, 2016 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced that SCIEX, a global leader in life science analytical technologies, will present and lead a precision medicine workshop on "New Innovations Towards Industrialized Proteomics" at the annual conference of the US Human Proteome Organization ("US HUPO").  US HUPO is being held from March 13-16 in Boston, MA. Representatives from SCIEX, Pressure BioSciences, Inc., and Advaita Bioinformatics will share insightful examples of how SCIEX next-generation solutions are enabling life science researchers to unlock the potential of their discoveries using industrialized omics to enable precision medicine. The workshop will showcase examples of how SCIEX's next-generation mass spectrometry-based solutions, combined with PBI's PCT platform and Advaita's iPathwayGuide, provide the ability to industrialize omics research workflows.

Life science researchers who are striving to transition from basic research to translational research will receive information about providing sample to biology solutions, as well as on accelerating and facilitating the biomarker research pipeline, from discovery and validation to translation into biologically and clinically relevant knowledge.  The workshop's seminars include:

Mark Cafazzo, Director of Academic Business at SCIEX.  Mr. Cafazzo will lead a practical discussion on new technologies for enabling reproducible and biologically meaningful results from proteomics experiments across very large sample cohorts in an effort to Industrialize Proteomics.

Vera Gross, Ph.D., Senior Scientist at PBI.  Dr. Gross' presentation, entitled "From PCT-HD to SWATH^® Data Acquisition in Half a Day", will include a discussion on advances of quantitative SWATH-MS technology with the introduction of new PCT-based sample preparation techniques and QC kits from PBI.

Andrew Olson, Vice-President of Business Development at Advaita Corporation.  Mr. Olsen will present an overview of the iPathway Guide for Next-Gen Proteomics, a cloud-enabled bioinformatics platform.

An audio recording will be made available after the conference.  Please contact SCIEX's media contact for access (Patrick Farrell, Sniper Public Relations on behalf of SCIEX, 603-420-8828).

About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 260 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.  

About SCIEX

SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company's global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research.

With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information, please visit sciex.com.  SCIEX social: Twitter: @SCIEXnews, LinkedIn and Facebook.

About Advaita Bioinformatics

Advaita Bioinformatics is a leader in the development of analytic solutions for high-throughput biological data.  Founded in 2005 with headquarters near Ann Arbor, Michigan, Advaita's novel analysis helps translate the terabytes of genomic data produced as a result of gene-expression and protein-expression experiments into a better understanding of the underlying biological phenomena.  Advaita's patented approach, called Impact Analysis, delivers results and insights that cannot be achieved with any other commercial analysis software.  iPathwayGuide is the first web application capable of identifying mechanisms of action, micro-RNAs, genetic variants, and potential drug targets, directly from gene-expression experiments.  This unique ability helps researchers quickly zero in on drug targets and validate drug candidates with the greatest potential for success while avoiding costly dead-ends.  For more information, please visit http://www.AdvaitaBio.com.

For more information about PBI and this press release, please click on the following website link: 
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter

Investor Contacts: 
Richard T. Schumacher, President & CEO, PBI 
(508) 230-1828 (T)         

Jeffrey N. Peterson, Chairman, PBI  
(650) 812-8121 (T)

Redwood Investment Group
(714) 978-4425 (T)

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pressure-biosciences-to-participate-in-sciex-workshop-on-new-innovations-towards-industrialized-proteomics-at-us-hupo-conference-300235369.html

SOURCE Pressure BioSciences, Inc.